Praxis Precision Medicines, Inc. (PRAX) 

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Show less

Over the last 12 months, insiders at Praxis Precision Medicines, Inc. have bought $35,962 and sold $0 worth of Praxis Precision Medicines, Inc. stock.

On average, over the past 5 years, insiders at Praxis Precision Medicines, Inc. have bought $2.55M and sold $16.25M worth of stock each year.

Highest buying activity among insiders over the last 12 months: DeSimone Jill (director) — $25,375. Souza Marcio (Chief Executive Officer) — $21,174.

The last purchase of 14,500 shares for transaction amount of $25,375 was made by DeSimone Jill (director) on 2023‑10‑05.